CD44 and neoplasm: Inhibitors such as exemestane, trametinib and statin exert profound antiproliferative effects on mesothelioma growth either by a direct downregulation of CD44 [45] or the suppression of CD44 and its associated signaling pathways [46, 47] attesting the critical role of CD44 in modulating tumor growth in MPM.